Trials / Conditions / Infection, Human Immunodeficiency Virus I

Infection, Human Immunodeficiency Virus I

21 registered clinical trials studyying Infection, Human Immunodeficiency Virus I.

Status	Trial	Sponsor	Phase
Completed	PRJ2203: Dolutegravir Post Authorization Safety Study (PASS) NCT03327740	ViiV Healthcare	—
Completed	A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™ NCT01597648	GlaxoSmithKline	Phase 1
Withdrawn	A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subject NCT01283100	ViiV Healthcare	Phase 1
Completed	A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial NCT01263015	ViiV Healthcare	Phase 3
Completed	ZIAGEN® Post-marketing Surveillance NCT01205243	ViiV Healthcare	—
Completed	A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily NCT01227824	ViiV Healthcare	Phase 3
Completed	KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects NCT00549198	GlaxoSmithKline	Phase 4
Completed	Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients NCT00481390	GlaxoSmithKline	—
Completed	Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Inf NCT00440947	ViiV Healthcare	Phase 3
Completed	HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Ad NCT00450580	ViiV Healthcare	Phase 3
Terminated	A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibito NCT00242879	ViiV Healthcare	Phase 2
Terminated	Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Sub NCT00197145	ViiV Healthcare	Phase 3
Terminated	GW873140 In Combination With Combivir In HIV Infected Subjects NCT00104429	ViiV Healthcare	Phase 2
Completed	Fosamprenavir Versus Other Protease Inhibitors NCT00094523	ViiV Healthcare	Phase 3
Terminated	GW873140 In Combination With Kaletra In HIV Infected Subjects NCT00102778	ViiV Healthcare	Phase 2
Completed	GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults NCT00257621	ViiV Healthcare	Phase 2
Completed	48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infectio NCT00089583	ViiV Healthcare	Phase 2
Completed	A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With NCT00082394	GlaxoSmithKline	Phase 4
Completed	Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected Dur NCT00242840	ViiV Healthcare	Phase 3
Completed	A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients NCT00046176	ViiV Healthcare	Phase 3
Completed	New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Su NCT00044577	ViiV Healthcare	Phase 3